Loading...
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus. This paper reviews the data supporting the use of vildagliptin...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3363148/ https://ncbi.nlm.nih.gov/pubmed/22661900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S31758 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|